Maha Othman: Establishing Pediatric Bleeding Assessment Cutoffs Through Global Research
Maha Othman, Co-Chairman SSC on Disseminated intravascular coagulopathy at International Society on Thrombosis and Haemostasis, shared a post on LinkedIn:
“Great to see the wealth and diversity of research at Queen’s Health Sciences
Particularly proud of Yousra Tera giving an excellent oral presentation from our WiCTEG cancer registry.
This is a prospective study to examine if thromboelastography can be integrated in a new thrombosis risk assessment tool to reduce the huge burden of cancer associated thrombosis in women with cancer under chemotherapy.
And
Ryan Babensee presenting an excellent poster on behalf of the large international team led by Dr. Paula James and myself to better define pediatric normal cut off for needing score using the standard ISTH bleeding assessment tool known as ISTH BAT This global effort and data from 7 countries and 5 continents Helen Okoye, Munira Borhany, Mozah AlMarshoudi, Margareth C Ozelo provided a solid clinically reliable cut off and was also presented at ISTH 2026 this past summer in Paris”

Find more posts featuring Maha Othman on Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian